- Home
- ZURA vs GRVY Comparison
ZURA vs GRVY Comparison
Compare ZURA & GRVY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | GRVY |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | South Korea |
| Employees | 40 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 426.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | ZURA | GRVY |
|---|---|---|
| Price | $4.37 | $62.23 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 627.8K | 26.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $54.54 |
| 52 Week High | $7.25 | $74.75 |
Technical Indicators
Market Signals| Indicator | ZURA | GRVY |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 49.38 |
| Support Level | $3.33 | $60.30 |
| Resistance Level | $4.58 | $65.34 |
| Average True Range (ATR) | 0.36 | 2.01 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 26.33 | 34.79 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.